1. Home
  2. LQDA vs VYX Comparison

LQDA vs VYX Comparison

Compare LQDA & VYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDA
  • VYX
  • Stock Information
  • Founded
  • LQDA 2004
  • VYX 1881
  • Country
  • LQDA United States
  • VYX United States
  • Employees
  • LQDA N/A
  • VYX N/A
  • Industry
  • LQDA Biotechnology: Pharmaceutical Preparations
  • VYX
  • Sector
  • LQDA Health Care
  • VYX
  • Exchange
  • LQDA Nasdaq
  • VYX Nasdaq
  • Market Cap
  • LQDA 1.4B
  • VYX 1.2B
  • IPO Year
  • LQDA 2018
  • VYX N/A
  • Fundamental
  • Price
  • LQDA $14.92
  • VYX $11.07
  • Analyst Decision
  • LQDA Strong Buy
  • VYX Strong Buy
  • Analyst Count
  • LQDA 8
  • VYX 5
  • Target Price
  • LQDA $27.13
  • VYX $14.60
  • AVG Volume (30 Days)
  • LQDA 2.1M
  • VYX 1.9M
  • Earning Date
  • LQDA 05-08-2025
  • VYX 05-08-2025
  • Dividend Yield
  • LQDA N/A
  • VYX N/A
  • EPS Growth
  • LQDA N/A
  • VYX N/A
  • EPS
  • LQDA N/A
  • VYX 6.72
  • Revenue
  • LQDA $14,144,000.00
  • VYX $2,733,000,000.00
  • Revenue This Year
  • LQDA $224.65
  • VYX N/A
  • Revenue Next Year
  • LQDA $250.54
  • VYX N/A
  • P/E Ratio
  • LQDA N/A
  • VYX $1.58
  • Revenue Growth
  • LQDA N/A
  • VYX N/A
  • 52 Week Low
  • LQDA $8.26
  • VYX $7.55
  • 52 Week High
  • LQDA $19.41
  • VYX $15.34
  • Technical
  • Relative Strength Index (RSI)
  • LQDA 45.94
  • VYX 64.15
  • Support Level
  • LQDA $13.94
  • VYX $10.38
  • Resistance Level
  • LQDA $17.88
  • VYX $11.36
  • Average True Range (ATR)
  • LQDA 1.40
  • VYX 0.31
  • MACD
  • LQDA -0.33
  • VYX 0.04
  • Stochastic Oscillator
  • LQDA 17.92
  • VYX 70.41

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About VYX NCR Voyix Corporation

NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in three reportable segments: Retail, Restaurants, and Digital Banking. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The Digital Banking segment serves financial institutions with cloud-based software solutions for a fully integrated digital banking experience across channels. Revenue sources include software sales and service support within each segment.

Share on Social Networks: